Articles, Blog

Mayo Clinic Center for Regenerative Medicine Biomaterials & Biomolecules cGMP Facility

March 1, 2020


Millions of people worldwide
suffer from deadly diseases, chronic conditions, and
congenital disorders that today have no cures. Often, only the
symptoms can be treated. Mayo Clinic, with sites
in Rochester, Minnesota, Scottsdale, Arizona,
and Jacksonville, Florida is committed to
transcending current treatment limitations by
advancing the science and practice of regenerative
medicine and surgery with a patient-centered,
team-based approach. Mayo Center for
Regenerative Medicine has created for platforms– the Advanced Products Incubator,
the Human Cell Therapy Laboratory, the Biotrust,
and the Biomaterials Facility to advance the rejuvenation,
replacement, and regeneration of diseased tissues in an
integrated and seamless manner. The Biomaterials Facility
will manufacture scaffolds that can be combined with
cells from the human cell laboratory in a clean room
under the rigorous guidelines of current good manufacturing
practices or CGMP. Following CGMP
accelerates the rate at which biomaterials and
regenerative technologies are translated from
bench to bedside. The first product manufactured
in the Biomaterials Facility will be a scaffold used in
the repair of peripheral nerve damage. Peripheral nerve
cells are long cells that have their nucleus in the
spinal cord and relay nerve signals through their
axons to the extremities, such as a hand or leg. If a portion of the
nerve is damaged or cut, the axons downstream degenerate. If the damage is
severe, the body is unable to repair
this damage alone. This is where
regenerative medicine is making a difference. A nerve scaffold that
will support axon growth is fabricated in the
biomaterials clean room from a novel
biodegradable polymer. It is tested for tensile
strength and biodegradeability. In the future, cells will
be added to the scaffold to repair long nerve gaps. These will either be cells
from a small skin nerve or a type of cell called
a fibroblast that is taken from the patient’s skin. In the Human Cell
Therapy Lab, the cells are put through a process
to reprogram them back to a stem cell-like state. The reprogrammed cells
are then grown in culture to number in the billions. To repair the nerve, the
patient undergoes surgery. One end of the scaffold is
attached to the downstream end of the damaged nerve. The reprogrammed stem cells are
injected into the other end, which is then sutured in place. The stem cells release
growth factors, which stimulate
the nerves Schwann cells to wrap themselves
around the axon and repair it. The axon grows
through the scaffold and into the normal nerve tissue
on the other side of the nerve gap. Signals can once
again be transmitted from the spinal cord
to the extremities. Eventually, the scaffold
will be absorbed by the body and become part of
the repaired nerve. The Biomaterials
Facility positions the Center for
Regenerative Medicine to be on the forefront of
private and public partnerships that can fast track clinical
trials for FDA approval of this and other new
regenerative therapies in cardiovascular, orthopedics,
neurosurgery, and plastic and reconstructive surgery.

1 Comment

  • Reply Mostafa mokar February 22, 2020 at 9:45 pm

    Interesting.
    Hi from Morocco

  • Leave a Reply